Please confirm you are human
(Sign Up for free to never see this)
← Back to Search
Self-associated Indisulam In Phospholipid-based Nanomicelles: A Potential Nanomedicine For Cancer.
H. Cesur, I. Rubinstein, A. Pai, H. Onyüksel
Published 2009 · Materials Science, Medicine
This study aimed to begin development of a nanomedicine containing indisulam solubilized in sterically stabilized micelles (SSMs) composed of DSPE-PEG(2000) or sterically stabilized mixed micelles (SSMMs) composed of DSPE-PEG(2000) plus egg phosphatidylcholine. Micelles were prepared by co-precipitation and reconstitution of drug and lipids. Particle size distributions of micellar formulations were determined by quasi-elastic light scattering. Amounts of solubilized drug were determined by reverse-phase high-performance liquid chromatography (RP-HPLC). In vitro cytotoxicity of indisulam in nanocarrier was determined on the MCF-7 cell line by the National Cancer Institute-developed sulforhodamine B assay. Optimal solubilized indisulam concentrations in 5 mM total lipid were 10 microg/mL for SSMMs and 400 microg/mL for SSMs. HPLC results demonstrated that the encapsulation capacity of both micelles was over 95%. In vitro studies showed that indisulam in micellar system was more effective than free indisulam. The optimized formulation was successfully freeze-dried without any addition of lyoprotectants or cryoprotectants. We conclude that SSMs are a promising nanocarrier for indisulam, and indisulam-SSMs should be developed further as a novel targeted nanomedicine.
This paper references
10.1023/A:1012287111922
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
C. Punt (2001)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1634/THEONCOLOGIST.12-4-375
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
D. Tripathy (2007)
Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
A. Yokoi (2002)
10.1016/S0022-1759(97)00137-3
Optimization of the sulforhodamine B colorimetric assay.
K. Papazisis (1997)
10.1038/nprot.2006.179
Sulforhodamine B colorimetric assay for cytotoxicity screening
V. Vichai (2006)
10.3109/9781420017267
Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs
J. Dressman (2007)
10.1200/JCO.2002.09.030
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
E. Raymond (2002)
10.1124/dmd.105.008326
SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES
A. Zandvliet (2006)
10.1023/A:1020488012264
Polyethylene Glycol-Diacyllipid Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice
A. Lukyanov (2004)
10.1002/JPS.20150
In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation.
B. Ashok (2004)
10.1023/A:1022243709003
Sterically Stabilized Phospholipid Mixed Micelles: In Vitro Evaluation as a Novel Carrier for Water-Insoluble Drugs
A. Krishnadas (2004)
10.1016/J.BMCL.2003.09.062
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
F. Abbate (2004)
10.1023/A:1010608317361
Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells
K. Fukuoka (2004)
10.1111/j.1349-7006.2005.00109.x
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
Y. Yamada (2005)
10.1201/9781315114361-15
Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
O. Koo (2005)
10.1038/sj.bjc.6603606
A phase I and pharmacokinetic study of indisulam in combination with carboplatin
C. Dittrich (2007)
10.1081/DDC-100102190
Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles.
M. A. Hammad (1999)
10.1016/j.ijpharm.2008.01.014
Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.
S. B. Lim (2008)
10.1023/A:1018847501985
A Novel Formulation of VIP in Sterically Stabilized Micelles Amplifies Vasodilation In Vivo
H. Önyüksel (2004)
10.1016/S0168-3659(02)00442-X
Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives.
J. X. Zhang (2003)
10.1093/ANNONC/MDI016
Phase II study of E7070 in patients with metastatic melanoma.
J. F. Smyth (2005)
10.1016/J.NANO.2005.06.004
Role of nanotechnology in targeted drug delivery and imaging: a concise review.
O. Koo (2005)
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a onehour infusion every three weeks in patients with advanced cancer
E Raymond (2002)
a concise review
OM Koo (2009)
10.1016/S0959-8049(01)00275-1
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
Y. Ozawa (2001)
10.1021/JM9902638
Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
T. Owa (1999)
10.1016/J.ADDR.2003.12.004
Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.
A. Lukyanov (2004)
10.1158/1535-7163.MCT-04-0234
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays
N. Nakatsu (2005)
This paper is referenced by
10.1016/j.ijpharm.2019.118586
Improved self-assembled micelles based on supercritical fluid technology as a novel oral delivery system for enhancing germacrone oral bioavailability.
Xuefeng Hou (2019)
10.2147/IJN.S25363
Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations
M. Sahib (2011)
10.1201/B11076-17
Phospholipid-based Nanomicelles in Cancer Nanomedicine
H. Onyuksel (2011)
10.1016/j.nano.2015.02.016
Intestinal absorption of fluorescently labeled nanoparticles.
S. Simović (2015)
10.2147/IJN.S118568
Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer
Y. Gu (2016)
10.1016/j.apsb.2019.07.003
Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats
Wen-hao Li (2020)
10.1201/B10846-10
Transmucosal and Ocular Drug Delivery
Vasant V. Ranade (2011)
10.1016/j.ijpharm.2016.02.019
Lipid-based nanoformulations for peptide delivery.
N. Matougui (2016)
10.1016/j.biomaterials.2011.01.038
The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
Hongjuan Yao (2011)
10.1208/s12249-014-0146-3
A New Lipid-Based Nano Formulation of Vinorelbine
F. Bahadori (2014)
10.1007/s11095-016-2021-2
A pH-Sensitive Nanocarrier for Tumor Targeting
Ligang Chen (2016)
10.1016/j.msec.2017.02.048
Heparin modified graphene oxide for pH-sensitive sustained release of doxorubicin hydrochloride.
Baomei Zhang (2017)
10.1016/j.jconrel.2017.06.019
Self‐assembled amphiphilic core‐shell nanocarriers in line with the modern strategies for brain delivery
Reham S. Elezaby (2017)
10.1016/B978-0-12-391860-4.00018-5
Nanomedicines for inflammatory diseases.
Fatima Khaja (2012)
Formulation and Characterization of Phospholipid Based Micelles: A Potential Carrier for Cancer
Mayank Chaudhari (2019)
A novel antineoplastic nano-lipobubble drug delivery system for passively targeted ovarian cancer therapy
Derusha Frank (2015)
10.1081/E-EBPPC-120050073
Nanoparticles: Cancer Management Applications
Shyamasree Ghosh (2017)
10.1016/B978-0-444-52824-7.00009-3
Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation
C. Avendaño (2008)
Developing health service delivery in a poor and marginalised community in North West Pakistan
Rajneet Kaur Khurana (2019)
10.1016/B978-0-444-62649-3.00010-7
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation: Kinase Inhibitors
C. Avendaño (2015)
10.1021/acsami.9b04051
pH-Responsive Nanoparticles Targeted to Lungs for Improved Therapy of Acute Lung Inflammation/Injury.
C. Zhang (2019)
10.1002/wnan.1185
Peptide delivery using phospholipid micelles.
A. Banerjee (2012)
10.1016/j.jconrel.2012.06.002
Improvement of drug safety by the use of lipid-based nanocarriers.
S. B. Lim (2012)
10.1007/978-3-319-11728-7_9
Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting
S. Ghosh (2015)
10.1002/ddr.21000
Incorporation of Beclomethasone Dipropionate into Polyethylene Glycol‐Diacyl Lipid Micelles as a Pulmonary Delivery System
Mohanad Naji Sahib (2012)
A Novel Anti-Diabetic Peptide Nanomedicine Against Pancreatogenic Diabetes
Amrita Banerjee (2012)
10.1016/j.bbrc.2018.01.042
Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer.
Nana Han (2018)
10.1007/s10989-012-9292-1
Sterically Stabilized Phospholipid Micelles Reduce Activity of a Candidate Antimicrobial Wound Healing Adjunct
R. Williams (2012)
10.1007/s13346-012-0107-x
VIP-targeted cytotoxic nanomedicine for breast cancer
Aparna Dagar (2012)
10.1201/B11076-17
Radiation Protection with Nanoparticles
C. Baker (2011)
10.1007/s40011-012-0080-7
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
10.1002/jps.24193
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Nilesh I. Gupta (2014)
See more